Surgical Site Infection Overview

Surgical Site Infections (SSI) are the most common nosocomial infection and frequently cause morbidity and mortality among inpatients of hospitals. The Centre for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) define SSI as postoperative infection occurring within 30 days of a surgical procedure (or within one year for permanent implants).


SSIs are classified as either incisional or organ/space, with incisional SSIs being further subclassified as superficial (involving only skin and subcutaneous tissue) versus deep (involving underlying soft tissue). Bacteria have mainly been associated with SSIs, and Staphylococcus aureus has been the most frequently reported causative agent.


Surgical Site Infection Market Report

The Surgical Site Infection (SSI) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted SSI symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Surgical Site Infection (SSI) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.


Request for sample–


Some of the key highlights of the surgical site infection market report

According to Delveinsight, total SSI cases in the 7MM was estimated to be 1.1 million in 2017 and is expected to grow by 2030.           
Assessments by DelveInsight’s analysts reveal that the United States accounted for highest incident cases of SSI as compared to EU5 countries and Japan.
Among the sub-types, superficial SSI had the maximum number of cases followed by organ/space and deep SSI cases.


Surgical Site Infection Market Companies

Destiny Pharma
Menarini Group Pharma
Botanix Pharma
Dr. Reddy’s Laboratories Ltd.
Zurex Pharma


Surgical Site Infection Market: Factors

Various factors contribute to the risk of SSI occurrence, and preventative measures require an integrative approach that focuses on pre-, intra- and post-operative care. Several patient characteristics have been shown to have a significant, independent association for SSI prediction. These include, but are not limited to, diabetes, cigarette smoking, obesity, and coincident remote site infections or colonization.


Surgical Site Infection Market Outlook

The market segment of this report is categorized into two sections: prophylactic therapy drug market from overall surgical procedures and surgical site infection (SSI) treatment drug market from SSI patient pool. The global therapeutic market of SSI treatment was estimated to be USD 855 million in 2017. Also, the total market size for prophylaxis treatment was USD 863 Million in 2017. The United States accounted for the highest share of both the market types among the 7MM, which was estimated to be USD 554 Million and USD 306 Million in SSI treatment and Prophylaxis, respectively, in 2017.


Surgical Site Infection Market: Forecast

The market forecast section of prophylactic therapy solely focuses on the market revenue generated by the topical or oral or injectable prophylactic antibiotics used for preoperative, intraoperative and postoperative procedures. The prophylactic therapy drug market is dominated by generic antibiotics, and most common drugs include antibiotics such as Cefazolin, Vancomycin, Cefuroxime, Clindamycin, Cefotetan, Metronidazole and Gentamicin. On the other hand, SSI treatment drug market is based on antibiotics such as Vancomycin and Linezolid (Cardiothoracic/related leg SSI) and Tigecycline IV (Abdominal SSI). Due to their easy availability and reach, these drugs have a higher rate of penetration in the market, thereby adding up to the total revenue generated.


Surgical Site Infection Market: Emerging Drugs

The dynamics of both the prophylactic and surgical site infection treatment market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecast period of 2020–2030. There are presently three emerging therapies focused on treating or preventing surgical site infection in either cardio or abdominal surgeries. These include XF-73 (Destiny Pharma Plc), D-PLEX100 (PolyPid Ltd.), BTX1801 (Botanix Pharmaceuticals) in the prophylactic segment, and Delafloxacin (Menarini Group) in SSI treatment section.


Buy a report-


Table of content

1. Key Insights

2. Report Introduction

3. Surgical Site Infection Prophylactic Market Overview at a Glance

4. Surgical Site Infection Treatment Market Overview at a Glance

5. Executive Summary of Surgical Site Infection

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Treatment and Management

9. Prevention

10. Organizations contributing towards Surgical Site Infection

11. Patient Journey

12. Case Report

13. Emerging Therapies

14. Surgical Site Infection: Seven Major Market Analysis

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight 


Surgical Site Infection Market Report Highlights

In the coming years, Surgical Site Infection (SSI) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Surgical Site Infection (SSI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for SSI. The launch of emerging therapies will significantly impact the Surgical Site Infection (SSI) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for SSI.
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.


Contact Us


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: